Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · IEX Real-Time Price · USD
7.71
+0.04 (0.52%)
Mar 28, 2024, 4:00 PM EDT - Market closed
Travere Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Year | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 - 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 145.24 | 109.46 | 131.84 | 198.32 | 175.34 | 164.25 | 154.94 | 133.59 | 99.89 | 28.2 | Upgrade
|
Revenue Growth (YoY) | 32.69% | -16.97% | -33.52% | 13.11% | 6.75% | 6.01% | 15.98% | 33.74% | 254.19% | - | Upgrade
|
Cost of Revenue | 11.45 | 4.42 | 3.82 | 6.13 | 5.23 | 5.53 | 3.61 | 4.55 | 2.19 | 0.57 | Upgrade
|
Gross Profit | 133.79 | 105.04 | 128.02 | 192.2 | 170.1 | 158.72 | 151.33 | 129.04 | 97.71 | 27.63 | Upgrade
|
Selling, General & Admin | 265.54 | 197.52 | 126.28 | 135.8 | 128.95 | 103.65 | 101.33 | 91.94 | 79.54 | 59.65 | Upgrade
|
Research & Development | 244.99 | 227.33 | 201.16 | 131.77 | 140.96 | 123.76 | 78.17 | 70.82 | 50.43 | 47.8 | Upgrade
|
Other Operating Expenses | 11.39 | 0 | 0 | 97.13 | 7.5 | -0.24 | 6.23 | 6.11 | 4.71 | 0 | Upgrade
|
Operating Expenses | 521.93 | 424.85 | 327.44 | 364.7 | 277.41 | 227.17 | 185.73 | 168.87 | 134.68 | 107.44 | Upgrade
|
Operating Income | -388.14 | -319.81 | -199.43 | -172.51 | -107.31 | -68.45 | -34.4 | -39.83 | -36.97 | -79.81 | Upgrade
|
Interest Expense / Income | 11.33 | 11.01 | 19.68 | 19.05 | 18.83 | 9.81 | 4.42 | 4.73 | 7.75 | 7.44 | Upgrade
|
Other Expense / Income | -288.3 | -52.66 | -39.43 | -2.77 | 20.31 | 23.61 | 19.54 | 13.02 | -150.19 | 26.16 | Upgrade
|
Pretax Income | -111.18 | -278.17 | -179.68 | -188.79 | -146.45 | -101.87 | -58.36 | -57.58 | 105.47 | -113.4 | Upgrade
|
Income Tax | 0.22 | 0.31 | 0.41 | -19.36 | -0.02 | 0.81 | 1.37 | -9.68 | -11.77 | -2.46 | Upgrade
|
Net Income | -111.4 | -278.48 | -180.09 | -169.43 | -146.43 | -102.68 | -59.73 | -47.9 | 117.24 | -110.94 | Upgrade
|
Shares Outstanding (Basic) | 74 | 64 | 60 | 48 | 42 | 40 | 39 | 37 | 34 | 25 | Upgrade
|
Shares Outstanding (Diluted) | 74 | 64 | 60 | 48 | 42 | 40 | 39 | 38 | 38 | 25 | Upgrade
|
Shares Change | 16.48% | 6.56% | 25.86% | 12.28% | 4.72% | 4.29% | 1.26% | 1.88% | 49.98% | 76.40% | Upgrade
|
EPS (Basic) | -1.50 | -4.37 | -3.01 | -3.56 | -3.46 | -2.54 | -1.54 | -1.29 | 3.49 | -4.43 | Upgrade
|
EPS (Diluted) | -1.50 | -4.37 | -3.01 | -3.56 | -3.46 | -2.54 | -1.54 | -1.29 | 3.17 | -4.43 | Upgrade
|
Free Cash Flow | -322.28 | -214.85 | -38.94 | -67.31 | -73.78 | -44.66 | -6.61 | -15.37 | -8.42 | -49.81 | Upgrade
|
Free Cash Flow Per Share | -4.34 | -3.37 | -0.65 | -1.42 | -1.74 | -1.10 | -0.17 | -0.41 | -0.25 | -1.99 | Upgrade
|
Gross Margin | 92.12% | 95.96% | 97.10% | 96.91% | 97.01% | 96.63% | 97.67% | 96.59% | 97.81% | 97.98% | Upgrade
|
Operating Margin | -267.24% | -292.17% | -151.27% | -86.98% | -61.20% | -41.68% | -22.20% | -29.82% | -37.01% | -282.98% | Upgrade
|
Profit Margin | -76.70% | -254.41% | -136.60% | -85.43% | -83.51% | -62.51% | -38.55% | -35.86% | 117.36% | -393.36% | Upgrade
|
Free Cash Flow Margin | -221.90% | -196.28% | -29.54% | -33.94% | -42.08% | -27.19% | -4.26% | -11.50% | -8.43% | -176.63% | Upgrade
|
Effective Tax Rate | - | - | - | - | - | - | - | - | -11.16% | - | Upgrade
|
EBITDA | -61.31 | -246.44 | -147.25 | -145.16 | -107.21 | -72.93 | -36.14 | -36.71 | 126.61 | -100.56 | Upgrade
|
EBITDA Margin | -42.21% | -225.14% | -111.69% | -73.19% | -61.15% | -44.40% | -23.32% | -27.48% | 126.74% | -356.56% | Upgrade
|
Depreciation & Amortization | 38.53 | 20.72 | 12.75 | 24.58 | 20.41 | 19.12 | 17.8 | 16.14 | 13.39 | 5.4 | Upgrade
|
EBIT | -99.84 | -267.16 | -160 | -169.74 | -127.62 | -92.06 | -53.94 | -52.85 | 113.22 | -105.96 | Upgrade
|
EBIT Margin | -68.74% | -244.07% | -121.36% | -85.59% | -72.79% | -56.05% | -34.81% | -39.56% | 113.34% | -375.72% | Upgrade
|